Next Century Growth Investors LLC Has $23.10 Million Stock Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Next Century Growth Investors LLC raised its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 286,937 shares of the company's stock after acquiring an additional 11,857 shares during the quarter. PROCEPT BioRobotics makes up approximately 1.7% of Next Century Growth Investors LLC's portfolio, making the stock its 11th biggest position. Next Century Growth Investors LLC owned 0.55% of PROCEPT BioRobotics worth $23,104,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in PRCT. Signaturefd LLC increased its position in shares of PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after acquiring an additional 145 shares during the period. Naviter Wealth LLC lifted its holdings in PROCEPT BioRobotics by 6.0% during the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company's stock worth $249,000 after buying an additional 176 shares during the last quarter. Amundi boosted its position in shares of PROCEPT BioRobotics by 0.9% during the 4th quarter. Amundi now owns 20,143 shares of the company's stock worth $1,742,000 after acquiring an additional 183 shares in the last quarter. Arizona State Retirement System raised its position in shares of PROCEPT BioRobotics by 1.5% during the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock worth $1,150,000 after acquiring an additional 218 shares in the last quarter. Finally, KRS Capital Management LLC boosted its holdings in PROCEPT BioRobotics by 0.5% in the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company's stock valued at $3,741,000 after purchasing an additional 225 shares in the last quarter. Institutional investors and hedge funds own 89.46% of the company's stock.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the transaction, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. The trade was a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at $9,875,374.20. This trade represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,455 shares of company stock valued at $368,322 over the last three months. 17.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on PRCT shares. Morgan Stanley dropped their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Truist Financial cut their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $91.43.

PROCEPT BioRobotics Stock Up 0.4 %

Shares of PRCT traded up $0.24 during mid-day trading on Thursday, reaching $53.05. 440,129 shares of the stock traded hands, compared to its average volume of 778,874. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of -27.19 and a beta of 1.09. The stock has a fifty day simple moving average of $59.75 and a 200 day simple moving average of $75.01. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a 12-month low of $47.04 and a 12-month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. Sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).